| 24.1199 0.275 (1.15%) | 09-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 29.88 | 1-year : | 33.04 |
| Resists | First : | 25.58 | Second : | 28.29 |
| Pivot price | 23.46  |
|||
| Supports | First : | 21.2 | Second : | 17.64 |
| MAs | MA(5) : | 23.43  |
MA(20) : | 24.31 |
| MA(100) : | 19.27 |
MA(250) : | 18.6 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 39.4 |
D(3) : | 32.5 |
| RSI | RSI(14): 53.2 |
|||
| 52-week | High : | 42.11 | Low : | 10 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ APLM ] has closed below upper band by 26.8%. Bollinger Bands are 57.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 24.7 - 24.8 | 24.8 - 24.9 |
| Low: | 21.95 - 22.05 | 22.05 - 22.15 |
| Close: | 23.95 - 24.12 | 24.12 - 24.28 |
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Thu, 24 Sep 2026
An amended Apollomics (APLM) insider report corrects an option's expiration date and accounts for 100 omitted shares. - Stock Titan
Thu, 24 Sep 2026
A director's 2,000 stock options expire in 2036, Apollomics (APLM) says in an amendment. - Stock Titan
Thu, 24 Sep 2026
Apollomics CFO acquires 10,000 shares as awards vest - Stock Titan
Fri, 18 Sep 2026
Price to sales forward of Apollomics Inc. – NASDAQ:APLM - TradingView
Thu, 17 Sep 2026
RSU vesting and options lift Apollomics (APLM) director to 2,000 shares - Stock Titan
Fri, 04 Sep 2026
Apollomics Inc. (APLM) Holds Steady at $27.5 as Shares Consolidate Between Key Levels - Range Breakout - careplusvn.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 553180 (%) |
| Held by Institutions | 74.1 (%) |
| Shares Short | 10 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.09e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -123.8 % |
| Operating Margin | 431.8 % |
| Return on Assets (ttm) | -57.7 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 8.84e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 199.58 |
| EBITDA (p.s.) | 5.77778e+006 |
| Qtrly Earnings Growth | -7.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.12 |
| Price to Cash Flow | -24.77 |
| Dividend | 0 |
| Forward Dividend | 6080 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|